112270-06-1

Basic information

• Product Name: ETHYL 2-CHLORO-6-HYDROXYBENZOATE
• Synonyms: ETHYL 2-CHLORO-6-HYDROXYBENZOATE;BENZOIC ACID, 2-CHLORO-6-HYDROXY-, ETHYL ESTER
• CAS NO: 112270-06-1
• Molecular Formula: C₉H₉ClO₃
• Molecular Weight: 200.61896
• Mol File: 112270-06-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 267.195 °C at 760 mmHg
• Flash Point: 115.396 °C
• Appearance: /
• Density: 1.301 g/cm³
• Vapor Pressure: 0.005mmHg at 25°C
• Refractive Index: 1.554
• Storage Temp.: 2-8°C
• CAS DataBase Reference: ETHYL 2-CHLORO-6-HYDROXYBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-CHLORO-6-HYDROXYBENZOATE(112270-06-1)
• EPA Substance Registry System: ETHYL 2-CHLORO-6-HYDROXYBENZOATE(112270-06-1)

Safety Data

• Hazardous Substances Data: 112270-06-1(Hazardous Substances Data)

Usage

General Description

Ethyl 2-Chloro-6-Hydroxybenzoate is a chemical compound belonging to the category of chlorobenzoic acids and derivatives. These compounds contain a benzoic acid in which one hydrogen of the benzene ring is substituted by a chlorine atom while an ethyl group is attached to its oxygen atom. The salient property of this chemical is its hydroxy functionality which contributes to its solubility in many organic solvents. This chemical is often synthesized in laboratory settings and may serve as an intermediate in various organic reactions. Its specific applications can vary widely depending on the reaction it is involved in. However, it's critical to handle this chemical appropriately as it can pose potential risks and hazards like many other chemicals.

InChI:InChI=1/C9H9ClO3/c1-2-13-9(12)8-6(10)4-3-5-7(8)11/h3-5,11H,2H2,1H3

Upstream product

• 112270-03-8 ethyl 3-chloro-2-(ethoxycarbonyl)hexa-2,4-dienoate 
• 172217-11-7 ethyl 2-amino-6-chlorobenzoate 
• 2148-56-3 2-chloro-6-aminobenzoic acid 
• 172217-16-2 ethyl 2-chloro-6-nitrobenzoate 
• 7664-93-9 sulfuric acid 
• 7335-25-3 ethyl 2-chlorobenzoate 
• 1847-87-6 ethyl 3-chlorophenyl carbonate 

Downstream Products

• 172217-12-8 ethyl 6-chloro-2-methoxybenzoate 
• 379230-44-1 ethyl 2-(allyloxy)-6-chlorobenzoate 
• 379230-43-0 6-chloro-1-benzofuran-7-amine 
• 379230-47-4 6-chloro-1-benzofuran-7-carboxylic acid 
• 412349-25-8 2-(4-chloro-3-ethoxycarbonyl-2-hydroxyphenyl)acetaldehyde 
• 379230-45-2 3-allyl-6-chloro-2-hydroxybenzoate 
• 3260-89-7 2-chloro-6-methoxybenzoic acid 
• 172217-13-9 ethyl 6-chloro-2-methoxycarbanilate 
• 1227416-20-7 C₂₁H₁₇ClN₄O₄ 

Relevant articles and documents

Anionic Fries rearrangement of aryl carbonates. A facile route to ortho-hydroxy esters

Aryl carbonates react with LDA or LiTMP to produce ortho-hydroxy esters.

QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS

The invention concerns quinazoline derivatives of Formula (I) wherein each of Q1, Z, m, R1, R2, R3 and Q2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease

Discovery of a New Class of Anilinoquinazoline Inhibitors with High Affinity and Specificity for the Tyrosine Kinase Domain of c-Src

Deregulated activity of the nonreceptor tyrosine kinase c-Src is believed to result in signal transduction, cytoskeletal and adhesion changes, ultimately promoting a tumor-invasive phenotype. We report here the discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of the c-Src enzyme. Special attention was directed toward finding inhibitors selective against KDR tyrosine kinase in order to ensure that the in vivo profile of a specific Src inhibitor could be determined. The 4-aminobenzodioxole quinazoline series gave compounds with excellent potency and selectivity. The most interesting compounds were evaluated in vivo and displayed good pharmacokinetics following oral dosing. Compounds such as the aminobenzodioxoles were shown to be potent inhibitors of tumor growth in a c-Src-transformed 3T3 xenograft model in vivo, resulting in more than 90% growth inhibition at doses as low as 6 mg/kg po once daily. Src tyrosine kinase inhibitors such as these may provide a novel therapeutic modality for targeting cancer invasion and metastasis.